Tyrosine News and Research

RSS

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).

26 Sep 2018

Phase 1 and 2 clinical trials of entrectinib drug in ROS1-positive NSCLC show promising results

Results of phase 1 and phase 2 clinical trials of the drug entrectinib in ROS1-positive non-small cell lung cancer presented on the press program of the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer show a response rate of 77.4 percent for 53 patients evaluable for response, with median duration of response of 24.6 months.

25 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

Exelixis, Inc. today announced that the National Comprehensive Cancer Network updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets.

7 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Scientists identify 'Achilles heel' of anaplastic large-cell lymphomas

Anaplastic large-cell lymphomas are rare cancers of the white blood cells. New research from the international ERIA consortium, led by scientists in Vienna, has now shown that the same signaling pathway is essential to the growth of cancer cells in various forms of ALCL: TYK2 (tyrosine kinase 2, an important component of the immune system) prevents apoptotic cell death by increasing the production of Mcl1, a special type of protein belonging to the BCL2 family.

3 Sep 2018

Modified Nurr1 protein may pave way for new Parkinson's therapy

Researchers have modified the protein Nurr1 so that it can enter cells from the outside. Nurr1 deficiency may be one of the causes of Parkinson's disease.

31 Aug 2018

Researchers discover potential new approach to block growth of HER2 positive breast cancer

Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer.

30 Aug 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

Ubiquigent launches REDOXprofiler for rapid identification of REDOX cycling compounds

Ubiquigent Limited, a company specializing in providing ubiquitin cell-signalling system drug discovery services, research tools and novel targeted chemistry, announced today that it has launched REDOXprofiler.

24 Aug 2018

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the European Commission has granted a marketing authorization for the oral receptor tyrosine kinase inhibitor LENVIMA (lenvatinib mesylate) as a single agent for the first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.

23 Aug 2018

Homogenous BTK occupancy assay used in tirabrutinib clinical studies

In a new SLAS Discovery article, Helen Yu and a team of researchers at Gilead Sciences, Inc. present a time-resolved fluorescence resonance energy transfer-based Bruton's tyrosine kinase occupancy assay that can measure target engagement in peripheral blood mononuclear cells and in lymph-node and bone-marrow samples.

17 Jul 2018

Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib with T-DM1 against heavily pretreated HER2-positive breast cancer.

11 Jul 2018

Researchers discover mechanism that shuts down cell-to-cell communications pathway

Cellular functions rely on several communications networks that allow cells to rapidly respond to signals affecting the organism.

10 Jul 2018

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Through x-ray crystallography and kinase-inhibitor specificity profiling, University of California San Diego School of Medicine researchers, in collaboration with researchers at Peking University and Zhejiang University, reveal that curcumin, a natural occurring chemical compound found in the spice turmeric, binds to the kinase enzyme dual-specificity tyrosine-regulated kinase 2 at the atomic level.

10 Jul 2018

Scientists create predictive model for neuroblastoma that incorporates early developmental signals

Neuroblastoma, a rare childhood cancer of the sympathetic nervous system, is particularly deadly because it is difficult to detect and thus generally advanced before treatment begins.

9 Jul 2018

Compounds found in green tea and red wine offer hope to treat inborn congenital metabolic diseases

A new Tel Aviv University study suggests there is hope of treating certain inborn congenital metabolic diseases -- a hope found in green tea and in red wine.

2 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

Penn research team identifies novel therapeutic target for heart disease

Changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart muscle cells, and reversing these modifications can lessen the stiffness and improve the beating strength of these cells isolated from transplant patients with heart failure, found researchers from the Perelman School of Medicine at the University of Pennsylvania.

12 Jun 2018